Methotrexate for maintenance of remission in Crohn's disease
- 31 December 2008
- reference entry
- review article
- Published by Wiley
- No. 4,p. CD006884
- https://doi.org/10.1002/14651858.CD006884.pub2
Abstract
Background Safe and effective long-term treatments that reduce the need for corticosteroids are needed for Crohn's disease. Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agents. Methotrexate may provide a safe and effective alternative to more expensive maintenance treatment with TNF-alpha antagonists. Objectives To conduct a systematic review of randomized trials examining the efficacy and safety of methotrexate for maintenance of remission in Crohn's disease. Search strategy The Cochrane Central Register of Controlled Trials (CENTRAL) Issue 2, 2009, PUBMED (1966 to April 2009), EMBASE (1984 to April 2009), DDW abstracts (1980 to 2008) and the Cochrane IBD/FBD Specialized Trials Register were searched. Study references and review papers were also searched for additional trials. Selection criteria Randomised controlled trials (RCTs) that compared methotrexate to placebo or any other active intervention for maintenance of remission in Crohn's disease were eligible for inclusion. Data collection and analysis Data extraction and assessment of methodological quality of included studies were independently performed by each author. The main outcome measure was the proportion of patients maintaining clinical remission as defined by the studies and expressed as a percentage of the total number of patients randomized (intention to treat analysis). Pooled odds ratios and 95% confidence intervals were calculated for dichotomous outcomes. Main results Three studies were included in the review. A pooled analysis (n = 98) including one high quality trail (n = 76) showed that intramuscular methotrexate (15 mg/week) was significantly more effective than placebo for maintenance of remission in Crohn's disease (OR 3.11; 95% CI 1.31 to 7.41; P = 0.01). The number needed to treat to prevent one relapse was 4. A pooled analysis of two small studies (n = 50) showed no difference between methotrexate and 6-MP for maintenance of remission (OR 2.63; 95% CI 0.74 to 9.37; P = 0.14). Adverse events were generally mild in nature and resolved upon discontinuation or with folic acid supplementation. Common adverse events included nausea and vomiting, symptoms of a cold, abdominal pain, headache, joint pain or arthralgia, and fatigue. Authors' conclusions Intramuscular methotrexate at a dose of 15 mg/week is safe and effective for maintenance of remission in Crohn's disease. Oral methotrexate (12.5 to 15 mg/week) does not appear to be effective for maintenance of remission in Crohn's disease.Keywords
This publication has 18 references indexed in Scilit:
- Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's diseasePublished by Wiley ,2009
- Long‐term results with azathioprine therapy in patients with corticosteroid‐dependent Crohn’s disease: Open‐label prospective studyJournal of Gastroenterology and Hepatology, 2007
- American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel DiseaseGastroenterology, 2006
- Corticosteroids for maintenance of remission in Crohn's diseaseEmergencias, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Methotrexate in Crohn's diseaseGut, 2001
- A randomized dose–response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitisAlimentary Pharmacology & Therapeutics, 1999
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996